- Home
- DMAC vs RCKY Comparison
DMAC vs RCKY Comparison
Compare DMAC & RCKY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- RCKY
- Stock Information
- Founded
- DMAC 2000
- RCKY 1932
- Country
- DMAC United States
- RCKY United States
- Employees
- DMAC N/A
- RCKY N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- RCKY Shoe Manufacturing
- Sector
- DMAC Health Care
- RCKY Consumer Discretionary
- Exchange
- DMAC Nasdaq
- RCKY Nasdaq
- Market Cap
- DMAC 178.0M
- RCKY 155.9M
- IPO Year
- DMAC N/A
- RCKY 1993
- Fundamental
- Price
- DMAC $3.76
- RCKY $23.74
- Analyst Decision
- DMAC Strong Buy
- RCKY Hold
- Analyst Count
- DMAC 2
- RCKY 1
- Target Price
- DMAC $8.00
- RCKY $20.00
- AVG Volume (30 Days)
- DMAC 307.4K
- RCKY 47.3K
- Earning Date
- DMAC 08-06-2025
- RCKY 07-29-2025
- Dividend Yield
- DMAC N/A
- RCKY 2.61%
- EPS Growth
- DMAC N/A
- RCKY 2.41
- EPS
- DMAC N/A
- RCKY 1.84
- Revenue
- DMAC N/A
- RCKY $454,939,000.00
- Revenue This Year
- DMAC N/A
- RCKY $6.67
- Revenue Next Year
- DMAC N/A
- RCKY $4.25
- P/E Ratio
- DMAC N/A
- RCKY $12.90
- Revenue Growth
- DMAC N/A
- RCKY N/A
- 52 Week Low
- DMAC $2.80
- RCKY $11.93
- 52 Week High
- DMAC $6.82
- RCKY $37.80
- Technical
- Relative Strength Index (RSI)
- DMAC 47.18
- RCKY 66.52
- Support Level
- DMAC $3.48
- RCKY $20.52
- Resistance Level
- DMAC $3.99
- RCKY $21.95
- Average True Range (ATR)
- DMAC 0.32
- RCKY 0.84
- MACD
- DMAC -0.00
- RCKY 0.09
- Stochastic Oscillator
- DMAC 41.01
- RCKY 92.80
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.